Gilead Sciences has promoted Andrew Cheng to Executive Vice President, HIV Therapeutics and Development Operations, and Taiyin Yang to the role of Executive Vice President, Pharmaceutical Development and Manufacturing. Both have joined Gilead’s senior leadership committee.
Cheng joined Gilead in 1999. He has led clinical development activities for the company’s development-stage programmes in HIV/AIDS. In 2009, he was appointed Senior Vice President, HIV Therapeutics and Development Operations, assuming additional responsibility for biometrics, clinical operations, clinical pharmacology, drug safety and public health, project management and regulatory affairs. He reports to Norbert Bischofberger, Executive Vice President, Research and Development and Chief Scientific Officer.
Yang joined Gilead in 1993 and was promoted to Senior Vice President in 2005. In her newly expanded role, Yang is responsible for managing pharmaceutical development, analytical operations, laboratory information, quality assurance and manufacturing of both clinical and commercial drug substance and drug product. She reports to Bischofberger and to John Milligan, President and Chief Operating Officer.
Prior to joining Gilead, Yang was Director of Analytical Chemistry at Syntex.
